跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
SOGROYA - Health Canada Drug Approval Details
Approvals
/
Health Canada
/
SOGROYA
Authorized
STANDARD
SOGROYA
Novo Nordisk Canada Inc
🇨🇦 Health Canada
Approval Date
Jul 4, 2025
Approval ID
cad6219eea95a879
Company
Novo Nordisk Canada Inc
Type
Standard
Approval Details
Approval Id
cad6219eea95a879
Drug Approval Canada Name
SOGROYA
Product Name
SOGROYA
Status
Marketed
Status Date
2023-11-27
Original Market Date
2023-11-27
Din
02539934
Drug Class
Human
Dosage Form
Solution
Route Of Administration
Subcutaneous
Schedule
Prescription , Schedule D
Ahfs
68:28.00
Atc Original
H01AC07 SOMAPACITAN
Atc Name
h 01 ac 07
Aig Number
0164861001
Company Name
Novo Nordisk Canada Inc
Company Address
101-2476 Argentia Road, Mississauga, Ontario, Canada, L5N 6M1
Active Ingredients
SOMAPACITAN
5 MG / 1.5 ML
Authorized
Quick Info
Agency
Health Canada
Country
🇨🇦
Approval Date
Jul 4, 2025
Approval ID
cad6219eea95a879
Type
Standard
Back to Health Canada Approvals